Skip to main content

Advertisement

SpringerLink
Log in

Ten years of HER2-directed therapy: still questions after all these years

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  2. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

    Article  PubMed  CAS  Google Scholar 

  3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  PubMed  CAS  Google Scholar 

  4. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  PubMed  CAS  Google Scholar 

  5. von Minckwitz G, Vogel P, Schmidt M et al (2007) Trastuzumab treatment beyond progression in patients with HER2-positive metastatic breast cancer the TBP study (GBG 26/BIG 3–05). Breast Cancer Res Treat 106:S185

    Google Scholar 

  6. Antoine E, Extra J, Vincent-Salomon L et al (2007) Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: results from the Hermine cohort study. Eur J Cancer Suppl 5:213 (Abstract 2099)

    Article  Google Scholar 

  7. Geyer CE, Martin A, Newstat B et al (2007) Lapatinib plus capecitabine in HER2-positive advanced breast cancer: Genomic and updated efficacy data. J Clin Oncol ASCO Annual Meeting Proceedings, Part I 25:1035

    Google Scholar 

  8. Modi S, Stopeck AT, Gordon MS et al (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25:5410–5417

    Article  PubMed  CAS  Google Scholar 

  9. Burstein H, Awada A, Badwe R et al (2007) HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer. Breast Cancer Res Treat 106:S268

    Google Scholar 

  10. Krop IE, Beeram M, Modi S et al (2007) A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2-positive breast cancer. Breast Cancer Res Treat 106:S33

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Ian E. Krop & Eric P. Winer

Authors
  1. Ian E. Krop
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric P. Winer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian E. Krop.

Additional information

This is a commentary to doi:10.1007/s10549-007-9885-0.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krop, I.E., Winer, E.P. Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Res Treat 113, 207–209 (2009). https://doi.org/10.1007/s10549-008-0041-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0041-2

Keywords

Search

Navigation